Cargando…

Economic burden and health-related quality of life in tenosynovial giant-cell tumour patients in Europe: an observational disease registry

BACKGROUND: Tenosynovial Giant-Cell Tumour (TGCT) is a benign clonal neoplastic proliferation arising from the synovium, causing a variety of symptoms and often requiring repetitive surgery. This study aims to define the economic burden—from a societal perspective—associated with TGCT patients and t...

Descripción completa

Detalles Bibliográficos
Autores principales: Lopez-Bastida, J., Aranda-Reneo, I., Rodríguez-Sánchez, B., Peña-Longobardo, L. M., Ye, X., Laeis, P., Fronk, E. M., Palmerini, E., Leithner, A., Van de Sande, M. A. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8254314/
https://www.ncbi.nlm.nih.gov/pubmed/34215312
http://dx.doi.org/10.1186/s13023-021-01883-5
_version_ 1783717703935066112
author Lopez-Bastida, J.
Aranda-Reneo, I.
Rodríguez-Sánchez, B.
Peña-Longobardo, L. M.
Ye, X.
Laeis, P.
Fronk, E. M.
Palmerini, E.
Leithner, A.
Van de Sande, M. A. J.
author_facet Lopez-Bastida, J.
Aranda-Reneo, I.
Rodríguez-Sánchez, B.
Peña-Longobardo, L. M.
Ye, X.
Laeis, P.
Fronk, E. M.
Palmerini, E.
Leithner, A.
Van de Sande, M. A. J.
author_sort Lopez-Bastida, J.
collection PubMed
description BACKGROUND: Tenosynovial Giant-Cell Tumour (TGCT) is a benign clonal neoplastic proliferation arising from the synovium, causing a variety of symptoms and often requiring repetitive surgery. This study aims to define the economic burden—from a societal perspective—associated with TGCT patients and their health-related quality of life (HRQOL) in six European countries. METHODS: This article analyses data from a multinational, multicentre, prospective observational registry, the TGCT Observational Platform Project (TOPP), involving hospitals and tertiary sarcoma centres from six European countries (Austria, France, Germany, Italy, the Netherlands, and Spain). It includes information on TGCT patients’ health-related quality of life and healthcare and non-healthcare resources used at baseline (the 12-month period prior to the patients entering the registry) and after 12 months of follow-up. RESULTS: 146 TGCT patients enrolled for the study, of which 137 fulfilled the inclusion criteria. Their mean age was 44.5 years, and 62% were female. The annual average total costs associated with TGCT were €4866 at baseline and €5160 at the 12-month follow-up visit. The annual average healthcare costs associated with TGCT were €4620 at baseline, of which 67% and 18% corresponded to surgery and medical visits, respectively. At the 12-month follow-up, the mean healthcare costs amounted to €5094, with surgery representing 70% of total costs. Loss of productivity represented, on average, 5% of the total cost at baseline and 1.3% at follow-up. The most-affected HRQOL dimensions, measured with the EQ-5D-5L instrument, were pain or discomfort, mobility, and the performance of usual activities, both at baseline and at the follow-up visit. Regarding HRQOL, patients declared a mean index score of 0.75 at baseline and 0.76 at the 12-month follow-up. CONCLUSION: The results suggest that TGCT places a heavy burden on its sufferers, which increases after one year of follow-up, mainly due to the healthcare resources required—in particular, surgical procedures. As a result, this condition has a high economic impact on healthcare budgets, while the HRQOL of TGCT patients substantially deteriorates over time. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13023-021-01883-5.
format Online
Article
Text
id pubmed-8254314
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-82543142021-07-06 Economic burden and health-related quality of life in tenosynovial giant-cell tumour patients in Europe: an observational disease registry Lopez-Bastida, J. Aranda-Reneo, I. Rodríguez-Sánchez, B. Peña-Longobardo, L. M. Ye, X. Laeis, P. Fronk, E. M. Palmerini, E. Leithner, A. Van de Sande, M. A. J. Orphanet J Rare Dis Research BACKGROUND: Tenosynovial Giant-Cell Tumour (TGCT) is a benign clonal neoplastic proliferation arising from the synovium, causing a variety of symptoms and often requiring repetitive surgery. This study aims to define the economic burden—from a societal perspective—associated with TGCT patients and their health-related quality of life (HRQOL) in six European countries. METHODS: This article analyses data from a multinational, multicentre, prospective observational registry, the TGCT Observational Platform Project (TOPP), involving hospitals and tertiary sarcoma centres from six European countries (Austria, France, Germany, Italy, the Netherlands, and Spain). It includes information on TGCT patients’ health-related quality of life and healthcare and non-healthcare resources used at baseline (the 12-month period prior to the patients entering the registry) and after 12 months of follow-up. RESULTS: 146 TGCT patients enrolled for the study, of which 137 fulfilled the inclusion criteria. Their mean age was 44.5 years, and 62% were female. The annual average total costs associated with TGCT were €4866 at baseline and €5160 at the 12-month follow-up visit. The annual average healthcare costs associated with TGCT were €4620 at baseline, of which 67% and 18% corresponded to surgery and medical visits, respectively. At the 12-month follow-up, the mean healthcare costs amounted to €5094, with surgery representing 70% of total costs. Loss of productivity represented, on average, 5% of the total cost at baseline and 1.3% at follow-up. The most-affected HRQOL dimensions, measured with the EQ-5D-5L instrument, were pain or discomfort, mobility, and the performance of usual activities, both at baseline and at the follow-up visit. Regarding HRQOL, patients declared a mean index score of 0.75 at baseline and 0.76 at the 12-month follow-up. CONCLUSION: The results suggest that TGCT places a heavy burden on its sufferers, which increases after one year of follow-up, mainly due to the healthcare resources required—in particular, surgical procedures. As a result, this condition has a high economic impact on healthcare budgets, while the HRQOL of TGCT patients substantially deteriorates over time. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13023-021-01883-5. BioMed Central 2021-07-02 /pmc/articles/PMC8254314/ /pubmed/34215312 http://dx.doi.org/10.1186/s13023-021-01883-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Lopez-Bastida, J.
Aranda-Reneo, I.
Rodríguez-Sánchez, B.
Peña-Longobardo, L. M.
Ye, X.
Laeis, P.
Fronk, E. M.
Palmerini, E.
Leithner, A.
Van de Sande, M. A. J.
Economic burden and health-related quality of life in tenosynovial giant-cell tumour patients in Europe: an observational disease registry
title Economic burden and health-related quality of life in tenosynovial giant-cell tumour patients in Europe: an observational disease registry
title_full Economic burden and health-related quality of life in tenosynovial giant-cell tumour patients in Europe: an observational disease registry
title_fullStr Economic burden and health-related quality of life in tenosynovial giant-cell tumour patients in Europe: an observational disease registry
title_full_unstemmed Economic burden and health-related quality of life in tenosynovial giant-cell tumour patients in Europe: an observational disease registry
title_short Economic burden and health-related quality of life in tenosynovial giant-cell tumour patients in Europe: an observational disease registry
title_sort economic burden and health-related quality of life in tenosynovial giant-cell tumour patients in europe: an observational disease registry
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8254314/
https://www.ncbi.nlm.nih.gov/pubmed/34215312
http://dx.doi.org/10.1186/s13023-021-01883-5
work_keys_str_mv AT lopezbastidaj economicburdenandhealthrelatedqualityoflifeintenosynovialgiantcelltumourpatientsineuropeanobservationaldiseaseregistry
AT arandareneoi economicburdenandhealthrelatedqualityoflifeintenosynovialgiantcelltumourpatientsineuropeanobservationaldiseaseregistry
AT rodriguezsanchezb economicburdenandhealthrelatedqualityoflifeintenosynovialgiantcelltumourpatientsineuropeanobservationaldiseaseregistry
AT penalongobardolm economicburdenandhealthrelatedqualityoflifeintenosynovialgiantcelltumourpatientsineuropeanobservationaldiseaseregistry
AT yex economicburdenandhealthrelatedqualityoflifeintenosynovialgiantcelltumourpatientsineuropeanobservationaldiseaseregistry
AT laeisp economicburdenandhealthrelatedqualityoflifeintenosynovialgiantcelltumourpatientsineuropeanobservationaldiseaseregistry
AT fronkem economicburdenandhealthrelatedqualityoflifeintenosynovialgiantcelltumourpatientsineuropeanobservationaldiseaseregistry
AT palmerinie economicburdenandhealthrelatedqualityoflifeintenosynovialgiantcelltumourpatientsineuropeanobservationaldiseaseregistry
AT leithnera economicburdenandhealthrelatedqualityoflifeintenosynovialgiantcelltumourpatientsineuropeanobservationaldiseaseregistry
AT vandesandemaj economicburdenandhealthrelatedqualityoflifeintenosynovialgiantcelltumourpatientsineuropeanobservationaldiseaseregistry